Investigating genetic factors in childhood cancer
Official title: Familial Investigations of Childhood Cancer Predisposition
Run by St. Jude Children's Research Hospital · NCT03050268 · Data updated 2026-11-12
This study is trying to find out if certain genes passed down in families can increase the risk of childhood cancer by looking at samples from kids who have had cancer and their relatives.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | St. Jude Children's Research Hospital Academic / other |
| Locations | 1 site (Memphis, Tennessee) |
| Status | Recruiting |
| Started | April 6, 2017 |
| Main results expected | March 31, 2037 |
| Study ends | March 31, 2037 |
| Registry record updated | June 17, 2026 |
| Trial ID | NCT03050268 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a personal or family history of childhood cancers, particularly those diagnosed under the age of 26.
✕Probably not a fit
Patients without a familial history of cancer or those diagnosed with cancer after the age of 26 may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the hereditary factors contributing to various childhood cancers by collecting blood, saliva, and tissue samples from participants. It focuses on families with a history of cancer, particularly those with members diagnosed at a young age. Participants will provide medical and family histories, and their biological samples will be analyzed for genetic changes associated with cancer predisposition. The study will also involve annual follow-ups to update health information and family history.
Why it matters
Potential benefit: If successful, this study could enhance understanding of genetic predispositions to childhood cancers, potentially leading to improved screening and prevention strategies.
How similar studies have gone: Other studies have shown success in identifying genetic predispositions in familial cancer cases, making this approach both relevant and promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing. DEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL: In this protocol, the definition of "Familial Cancer" is met if any of the following is present: * An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR * An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR * An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR * An individual with a congenital cancer diagnosed before 6 months of age; OR * An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age º Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults. INCLUSION CRITERIA: * An individual who meets this protocol's definition of "Familial Cancer," as above. * Biologic relatives of an individual meeting this protocol's definition of "Familial Cancer," who are either affected or unaffected by cancer. EXCLUSION CRITERIA: * An inability or unwillingness of the research participant or his/her legally authorized representative (LAR) to provide written informed consent. * The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.
Where it's running
-
St. Jude Children's Research Hospital
Memphis, Tennessee, United States Recruiting
Study contacts
- Principal investigator: Kim E. Nichols, MD — St. Jude Children's Research Hospital
- Study coordinator: Kim E. Nichols, MD
- Email: referralinfo@stjude.org
- Phone: 888-226-4343
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding genetic causes of neuroendocrine tumors in Mexican patients
This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.
-
Stem cell transplantation for blood disorders using specific cell depletion techniques
This study is testing a new way of using stem cell transplants for children and young adults with blood disorders to see if removing certain cells helps them recover better and improve their quality of life.
-
Transplantation with modified stem cells and Zoledronate for pediatric cancers
This study is testing a new way to use modified stem cells and a drug called Zoledronate to see if it can safely help children with tough-to-treat cancers.
-
Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS
This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.
-
Study of crushed venetoclax tablets dissolved in liquid for pediatric patients
This study tests if crushing venetoclax tablets and mixing them with liquid helps children with blood cancers absorb the medication better and stay safe while taking it.
-
Using Tagraxofusp to treat pediatric patients with relapsed or refractory blood cancers
This study is testing a new drug called Tagraxofusp to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.